Michelle A Fravel

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. doi Management of gout in the older adult
    Michelle A Fravel
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    Am J Geriatr Pharmacother 9:271-85. 2011
  2. doi Special considerations for treatment of type 2 diabetes mellitus in the elderly
    Michelle A Fravel
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA 52242 5000, USA
    Am J Health Syst Pharm 68:500-9. 2011
  3. doi Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout
    Michael E Ernst
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    Clin Ther 31:2503-18. 2009

Collaborators

Detail Information

Publications3

  1. doi Management of gout in the older adult
    Michelle A Fravel
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    Am J Geriatr Pharmacother 9:271-85. 2011
    ..Management of gout in elderly subjects can be complicated by comorbidities and polypharmacy...
  2. doi Special considerations for treatment of type 2 diabetes mellitus in the elderly
    Michelle A Fravel
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA 52242 5000, USA
    Am J Health Syst Pharm 68:500-9. 2011
    ..The intensity and selection of therapy for the treatment of type 2 diabetes mellitus in elderly patients are discussed...
  3. doi Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout
    Michael E Ernst
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    Clin Ther 31:2503-18. 2009
    ..Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout...